OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Goldberg on Precision Medicine in Hematologic Malignancies

March 2nd 2018

Stuart L. Goldberg, MD, chief medical officer, John Theurer Cancer Center, discusses precision medicine for patients with hematologic malignancies.

Dr. Rugo Discusses Advancements With Biosimilars

March 2nd 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses recent advancements with biosimilars.

Dr. Perl Discusses the Impact of the ELIANA Trial

March 1st 2018

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the impact of the ELIANA trial in acute lymphoblastic leukemia (ALL).

Dr. Isaacs Discusses Antibody Drug Conjugates in TNBC

March 1st 2018

Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses antibody drug conjugates in the treatment of patients with triple-negative breast cancer.

Dr. Freedland on Diet and Lifestyle Interventions in Patients With Prostate Cancer

March 1st 2018

Stephen J. Freedland, MD, director, Center for Integrated Research in Cancer and Lifestyle, co-director, Cancer Genetics and Prevention Program, associate director, Faculty Development Samuel Oschin Comprehensive Cancer Institute, professor of surgery, Cedars-Sinai Medical Center, discusses nuanced diet and lifestyle interventions in patients with prostate cancer.

Dr. Daskivich on Imaging Modalities in Prostate Cancer

March 1st 2018

Timothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses developing and available imaging modalities in prostate cancer.

Dr. Figlin on the Safety Profile of Immuno-Oncology Agents in Kidney Cancer

March 1st 2018

Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the tolerability and toxicity of immune-oncology agents in kidney cancer.

Dr. Posadas on the Use of Circulating Tumor Cells in mCRPC

March 1st 2018

Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor of medicine, Cedars-Sinai Medical Center, discusses the future of detection in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Catenacci on Study of Margetuximab Plus Pembrolizumab in Gastric/GEJ Cancer

March 1st 2018

Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, University of Chicago Medicine, discusses a study of margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) in gastroesophageal junction (GEJ) or gastric adenocarcinoma.

Dr. Luke Discusses Noncutaneous Melanoma

March 1st 2018

Jason J. Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses noncutaneous melanoma.

Dr. Schuster Dicsusses CAR T-Cell Therapy in DLBCL

March 1st 2018

Stephen J. Schuster, MD, professor of hematology/oncology at the University of Pennsylvania Abramson Cancer Center, discusses CAR T-cell therapy in diffuse large B-cell lymphoma.

Dr. Richter on Toxicities of Treatments for Multiple Myeloma

February 28th 2018

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center, discusses toxicities in the treatment of patients with multiple myeloma.

Dr. Singh Discusses Challenges for GIST

February 28th 2018

Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses challenges for patients with gastrointestinal stromal tumors (GIST).

Dr. O'Malley on the Tolerability of PARP Inhibitors in Ovarian Cancer

February 28th 2018

David O'Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the tolerability of PARP inhibitors for patients with ovarian cancer.

Dr. Bryce on the Use of Abiraterone Versus Docetaxel in Patients With Prostate Cancer

February 28th 2018

Alan H. Bryce, MD, assistant professor of medicine, Mayo Clinic, discusses the importance of individualized approaches in the use of abiraterone (Zytiga) versus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Dr. Castle on Adjuvant Versus Early Salvage Therapy in Prostate Cancer

February 28th 2018

Erik P. Castle, MD, professor of urology, Mayo Clinic, discusses the use of adjuvant versus early salvage therapy in patients with prostate cancer, citing his own preference for early salvage therapy.

Dr. Younes Discusses Ibrutinib Plus Nivolumab in NHL

February 27th 2018

Anas Younes, MD, Chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the combination of ibrutinib (Imbruvica) plus nivolumab (Opdivo) in non-Hodgkin lymphoma.

Dr. He on the Future of Precision Medicine in GI Malignancies

February 27th 2018

Aiwu Ruth He, MD, PhD, associate professor of medicine, Georgetown-Lombardi Comprehensive Cancer Center, discusses the future of precision medicine in gastrointestinal malignancies.

Dr. Morse Reflects on Recent Data in Advanced CRC

February 27th 2018

Michael A. Morse, MD, professor, Medicine, Department of Surgery, Duke University School of Medicine, Duke Cancer Institute, reflects on recent data in advanced colorectal cancer.

Dr. DeAngelo Discusses Ongoing Trials in AML

February 27th 2018

Daniel J. DeAngelo, MD, PhD, medical oncologist, Dana-Farber Cancer Institute, discusses ongoing trials of patients with acute myeloid leukemia (AML).